COVID-19 and exacerbation of dermatological diseases: A review of the available literature.
Khashayar AramAnant D PatilMohamad GoldustFateme RajabiPublished in: Dermatologic therapy (2021)
Since the emergence of the new coronavirus disease 19 (COVID-19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare-ups of underlying dermatologic disease in patients with COVID-19. A total of 17 articles were recovered reporting on flare-ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus erythematosus, acrodermatitis continua of Hallopeau, systemic sclerosis sine scleroderma, and Sézary syndrome (SS). Out of these, psoriasis and alopecia areata were the most common conditions. However, most cases of psoriasis could have been attributed to either antimalarial agents that were initially used for the treatment of COVID-19 or discontinuation of treatment following SARS-CoV2 infection.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- systemic sclerosis
- interstitial lung disease
- chronic obstructive pulmonary disease
- systematic review
- rheumatoid arthritis
- emergency department
- atopic dermatitis
- replacement therapy
- disease activity
- risk assessment
- climate change
- human health
- smoking cessation